Certain formulary changes during the plan year prohibition provision and medical assistance program formulary changes implementation for certain enrollees prohibition provision
SF1806 limits when health plans and the state Medical Assistance program may change prescription drug formularies for people who are already using a drug. For private health plans, the bill generally prohibits removing a drug from a formulary or moving it to a higher-cost benefit category during an enrollee’s plan year if the enrollee was previously prescribed that drug, with exceptions for drugs deemed unsafe, withdrawn, or subject to new evidence of imminent patient harm. It also allows a formulary change when a brand-name drug is replaced by a therapeutically equivalent generic or interchangeable biologic at the same or lower cost, so long as 60 days’ notice is given to prescribers, pharmacists, and affected enrollees.
For Medical Assistance, the bill adds a similar protection: if the commissioner removes a drug from the Medicaid formulary, enrollees who were already prescribed the drug during the calendar year generally keep coverage at the same level until the following January 1. The same safety-based exceptions apply, and the bill also permits removal of a brand-name drug when a lower-cost therapeutically equivalent or interchangeable alternative is added with 60 days’ notice. The Medicaid provisions are effective January 1, 2026, or upon federal approval, whichever is later; the private-market provisions are effective January 1, 2026.
The bill’s impact is to constrain mid-year formulary changes that can disrupt ongoing treatment and increase out-of-pocket costs for patients. It would amend Minnesota Statutes section 256B.0625, subdivision 13, and create new chapter 62Q section 62Q.83, affecting health plans, pharmacy benefit managers, prescribers, pharmacists, enrollees, and Medical Assistance recipients. It preserves flexibility for safety-related drug removals and for substitutions to lower-cost generics or interchangeable biologics.
The overall sentiment appears supportive of patient continuity and medication access, with the bill framed as a consumer-protection measure. The absence of recorded votes or committee transcript detail limits the ability to identify specific debate, but the structure of the bill suggests a policy balance between protecting patients from disruptive formulary changes and preserving plan authority to respond to safety concerns and cost-saving substitutions.
The main point of contention is likely the tradeoff between patient stability and payer flexibility. Health plans and Medicaid administrators may view the restrictions as limiting formulary management and cost control during the plan year, while patients, prescribers, and pharmacists are likely to favor the added predictability and continuity of coverage. The 60-day notice requirement and the exceptions for unsafe or withdrawn drugs are the bill’s key compromise features.
The bill would add a new statutory section in chapter 62Q governing private health plan formulary changes and amend Minnesota’s Medical Assistance drug coverage statute, section 256B.0625, subdivision 13. It would prohibit most mid-year formulary removals or cost increases for drugs already prescribed to an enrollee, while allowing exceptions for safety-related changes and for substitutions to therapeutically equivalent generics or interchangeable biologics with advance notice. For Medical Assistance, it would require continued coverage at the prior level through the end of the calendar year for enrollees already using a drug before it is removed from the formulary, subject to similar exceptions. These changes would affect health plans, Medicaid coverage administration, pharmacy benefit managers, prescribers, pharmacists, and enrollees, and would take effect in 2026, with the Medicaid portion contingent on federal approval.
The bill appears to have a generally favorable, patient-centered policy orientation, emphasizing continuity of treatment and protection from unexpected cost increases. Because there are no recorded votes or committee transcripts provided, there is no direct evidence of opposition or amendment debate in the available materials. The bill’s exceptions for unsafe drugs and lower-cost therapeutic substitutes suggest an attempt to balance consumer protections with clinical safety and cost containment.
The likely contention centers on whether the bill unduly restricts health plans and the Medical Assistance program from managing formularies and controlling drug spending during the year. Supporters would likely emphasize that patients should not be forced to switch medications or pay more mid-year when they are already stable on a prescribed drug. Opponents or cost-conscious stakeholders may argue that the restrictions reduce flexibility to respond to pricing changes, utilization management needs, and formulary negotiations, though the bill’s safety exceptions and substitution provisions are designed to address some of those concerns.